Boost for NSW spinal injury research
29 January, 2003 by Susan WilliamsonNSW Premier Bob Carr has pledged $AUD10.9 million towards research into spinal injury.
Former telco ventures into biotech with Burnet deal
24 January, 2003 by Melissa TrudingerFormer telecommunications company Select-Tel is the latest to venture into biotech, signing a memorandum of understanding with Melbourne's MacFarlane Burnet Institute for Medical Research and Public Health to commercialise several projects from the Institute.
New genetic theory claims epileptics may cop a double whammy
23 January, 2003 by Graeme O'NeillSome individuals born into families with a history of epilepsy may be doubly, even triply cursed, according a new theoretical model of the world's most common inherited brain disorder.
Melbourne research aims to show how Epstein is barred
17 January, 2003 by Melissa TrudingerResearchers from Monash and Melbourne Universities investigating the immune response toward the Epstein-Barr virus (EBV) have used crystallographic techniques to visualise the shape of the T-cell receptor that specifically prevents the virus from wreaking havoc.
Amrad mystified by shareholder splurge
13 January, 2003 by Pete YoungMelbourne biotech Amrad Corp says it is mystified by a sudden flurry of investor interest that drove its share price up 50 per cent last week and sparked a formal query from the Australian Stock Exchange.
Meditech considers large-scale m'facture after discoveries
19 December, 2002 by Melissa TrudingerResearchers, funded by Meditech, at Curtin University of Technology in Perth have identified carbohydrate compounds that specifically bind to proteins involved in asthma, atopic dermatitis and other inflammatory responses.
Canon deal to net Psiron $US1m, royalties
17 December, 2002 by Melissa TrudingerSydney biotech company Psiron has signed a memorandum of understanding (MoU) with Canon, providing the Japanese company with exclusive worldwide rights to the Vapotronics inhaled drug delivery system in return for an up-front payment of $US1 million and potentially substantial royalties.
Garvan teams with Benitec in diabetes genetics project
16 December, 2002 by Pete YoungSydney's Garvan Institute of Medical Research is collaborating with gene silencing specialist Benitec to probe the role of specific genes in type 2 diabetes.
Q-Vis calls in administrators
16 December, 2002 by Pete YoungPerth biotech Q-Vis Ltd is in the hands of administrators Ferrier Hodgson after coming up empty-handed from a six-month search for a strategic partner with deep pockets.
Melbourne researchers discover malaria resistance mutation
11 December, 2002 by Melissa TrudingerA new pathway for the invasion of red blood cells by the malaria parasite Plasmodium falciparum has been discovered by Melbourne researchers based at the Walter and Eliza Hall Institute.
Learning about liver tissue
04 December, 2002 by Pete YoungA group of Australian researchers are pursuing ground-breaking work on receptors in muscle tissue which play an unexpectedly important part in regulating cholesterol levels.
Australian HIV vaccine trial touted for 2003
03 December, 2002 by Melissa TrudingerA public consortium of researchers is hoping to get permission to start a Phase I clinical trial of a new HIV vaccine early in the new year.
Peptech MD moves to sweeten $8.9m loss
03 December, 2002 by Graeme O'NeillPeptech managing director Stephen Kwik is accentuating the positives after Peptech reported an after-tax loss of $AU8.9 million loss in the 12 months to September, after a $AU32.7 million net profit in the previous year.
Researchers get closer to malaria vaccine
02 December, 2002 by Pete YoungThe hunt for an anti-malaria vaccine is hotting up thanks to Australian researchers who have shown for the first time that T-cells can provide cell-based immunity in humans against the red blood cell stage of malaria.
Antisense Therapeutics placement beats expectations
02 December, 2002 by Melissa TrudingerAntisense Therapeutics has raised $500,000 over its expected $4 million in an oversubscribed share placement that closed two days earlier than originally planned.
